OBJECTIVE: As transforming growth factor-beta1 (TGF-beta1) determines important neurotrophic and neuroprotective actions, we postulated serum TGF-beta1 levels could be low in Alzheimer's disease (AD), and TGF-beta1 genetic variation could be associated with AD risk through modulating serum TGF-beta1 levels. METHODS: TGF-beta1 (-800) (rs 1800468), (-509) (rs 1800469) and (+869) (rs 1982073) polymorphisms were genotyped in 412 AD patients and 406 controls. We measured serum TGF-beta1 levels (by ELISA) in 63 AD patients and compared them with 77 age- and gender-matched non-demented controls. RESULTS: Serum TGF-beta1 levels were not different in AD patients than in controls. Distribution of the allele and genotype frequencies of TGF-beta1 polymorphisms did not differ between AD patients and controls. There was no significant correlation between serum TGF-beta1 levels and TGF-beta1 polymorphisms. CONCLUSION: Serum TGF-beta1 concentration is not a potential biomarker for AD, and TGF-beta1 genetic variants (-800, -509, and +869) are not risk factors for AD.
OBJECTIVE: As transforming growth factor-beta1 (TGF-beta1) determines important neurotrophic and neuroprotective actions, we postulated serum TGF-beta1 levels could be low in Alzheimer's disease (AD), and TGF-beta1 genetic variation could be associated with AD risk through modulating serum TGF-beta1 levels. METHODS:TGF-beta1 (-800) (rs 1800468), (-509) (rs 1800469) and (+869) (rs 1982073) polymorphisms were genotyped in 412 ADpatients and 406 controls. We measured serum TGF-beta1 levels (by ELISA) in 63 ADpatients and compared them with 77 age- and gender-matched non-demented controls. RESULTS: Serum TGF-beta1 levels were not different in ADpatients than in controls. Distribution of the allele and genotype frequencies of TGF-beta1 polymorphisms did not differ between ADpatients and controls. There was no significant correlation between serum TGF-beta1 levels and TGF-beta1 polymorphisms. CONCLUSION: Serum TGF-beta1 concentration is not a potential biomarker for AD, and TGF-beta1 genetic variants (-800, -509, and +869) are not risk factors for AD.
Authors: Timo Jan Oberstein; Lava Taha; Philipp Spitzer; Janina Hellstern; Martin Herrmann; Johannes Kornhuber; Juan Manuel Maler Journal: Front Immunol Date: 2018-06-04 Impact factor: 7.561
Authors: Annamaria Cattaneo; Nadia Cattane; Chiara Malpighi; Darina Czamara; Anna Suarez; Nicole Mariani; Eero Kajantie; Alessia Luoni; Johan G Eriksson; Jari Lahti; Valeria Mondelli; Paola Dazzan; Katri Räikkönen; Elisabeth B Binder; Marco A Riva; Carmine M Pariante Journal: Mol Psychiatry Date: 2018-01-04 Impact factor: 15.992
Authors: María Elena Soto; Claudia Huesca-Gómez; Yazmín Torres-Paz; Giovanny Fuentevilla-Álvarez; Ricardo Gamboa Journal: Int J Environ Res Public Health Date: 2019-12-03 Impact factor: 3.390